Since the beginning of the pandemic, the Medicine Quality Research Group has identified 845 articles relevant to medical product quality issues for COVID-19.
Universal access to quality-assured medicines and vaccines, to be achieved among other things by strengthening the pharmaceutical and regulatory systems, is a priority for several Belgian actors, including the DGD, ITM and Be-cause health, and their partners. Unfortunately, the COVID-19 pandemic has further highlighted the difficulty for health systems in low- and middle-income countries to guarantee the quality of the products needed to care for their populations. The University of Oxford, through its reports on COVID-19 health products, has documented numerous cases of substandard or falsified products in these countries since 2020 (Medical Product Quality Reports | Infectious Diseases Data Observatory (iddo.org)). Thanks to the support of the Belgian Directorate General for Development Cooperation and Humanitarian Aid (DGD) through its framework agreement with the ITM, the most recent version of these reports is now also available in French. You can download it here, for your information and to share with all other colleagues and institutions concerned.
Meer nieuws over
PUBLIC HEALTH BUITEN LAND